Paediatric Vaccine Market Set for Significant Growth, Projected to Reach USD 184,706.7 Million by 2033 at a 13.1% of CAGR

The global paediatric vaccine market is valued at USD 54,130.1 million in 2023 and is expected to experience robust growth, with a remarkable CAGR of 13.1% over the forecast period. By 2033, the market is anticipated to reach a valuation of USD 184,706.7 million, reflecting the growing demand for vaccines to protect children from a wide range of preventable diseases.

This expansion is driven by increasing awareness of vaccination benefits, rising healthcare investments, and advancements in vaccine technologies. As governments and healthcare organizations continue to prioritize child health, the paediatric vaccine market is poised for significant growth in the coming years.

Production and Distribution Analysis in the Paediatric Vaccine Market

• The population is not only aware of the risks possessed by diseases like measles, influenza, and polio but also of the importance of warding them off early, thus generating the demand for infant vaccines.
• The increase in the population, resulting in a booming number of births, aids the paediatric vaccine market as parents seek to safeguard their children and mothers with the help of paediatric vaccines.
• The eruption of the pandemic changed the focus of the paediatric vaccine producers as they sought to address the looming threat while giving some short shrift to other paediatric vaccines. The paediatric vaccine market is back in the swing of things as vaccine-approval levels are approaching pre-pandemic levels again in the United States.
• The high cost associated with developing and maintaining vaccines is a challenge for paediatric vaccine manufacturers.
• The widespread acceptance of paediatric vaccines is augmented by support from governments all over the world, who are launching schemes and adopting policies beneficial to the paediatric vaccine market.

Competitive Landscape in the Paediatric Vaccine Market

The paediatric vaccine suppliers are increasingly leveraging the benefits of collaborations. Partnerships with healthcare institutions, mergers with other manufacturers in the market, acquisitions, and collaborative strategies are some of the strategies adopted by paediatric vaccine suppliers.

The paediatric vaccines market does not feature manufacturers that are highly dominant. Instead, the market is fragmented, with several key players enjoying their share of the pie. The producers of paediatric vaccines are also receiving increasing approvals from health regulators to distribute their vaccines.

Recent Developments in the Paediatric Vaccine Market

• On June 30, 2023, SK Bioscience Ltd. and Sanofi Pasteur SA reported positive data from their 21-valent pneumococcal conjugate vaccine (PCV) vaccine study.
• In May 2023, the FDA approved vaccines from companies GSK plc and Pfizer Inc. for respiratory syncytial virus (RSV) treatment. These are the first vaccines approved by the FDA for RSV treatment. Meissa Vaccines Inc. has also reported positive results from trials of its RSV vaccine.
• On 31 August 2022, Pfizer Inc and BioNTech SE announced that the FDA had approved their Covid-19 vaccine booster dose for people of 12 years or older.
• In June 2022, GlaxoSmithKline Plc announced that its vaccine for the prevention of measles, mumps, and rubella in people over the age of one year got approval from the FDA.

Key Companies in the Paediatric Vaccine Market

• GlaxoSmithKline Plc
• Merck & Co. Inc
• Pfizer Inc.
• Sanofi SA
• Panacea Biotec
• Zydus Cadila
• Emergent BioSolutions Inc
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech and Indian Immunological
• Catalent Inc
• Robinson Pharma Inc.
• Hunan Er-Kang Pharmaceutical Co. Ltd.
• Procaps
• CAPTEK Softgel International Inc
• Softcaps Fuji Capsule Co. Ltd.
• Aenova Holding GmbH
• Sirio Pharma Co. Ltd.
• Bahrain Pharma
• Sinovac Biotech Ltd
• AstraZeneca Plc
• Meissa Vaccines Inc

Get the Comprehensive Full Report Now

Key segments

By Indication:

• Pneumococcal Conjugate Vaccine
• DTP Vaccine
• Influenza
• Meningococcal Vaccine
• Polio Vaccine
• Rotavirus Vaccine
• MMR Vaccine
• Varicella Virus Vaccine

By Technology:

• Live or Attenuated Vaccine
• Inactivated or Killed Vaccine
• Toxoid Vaccine
• Conjugate Vaccine
• Subunit Vaccine
• Recombinant Vector Vaccine

By Vaccine:

• Monovalent Vaccines
• Multivalent Vaccines

By End-use Sector:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Health Centres

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube